Omar Nadeem

Dec 3, 2024 | cancernetwork.com | Omar Nadeem

December 3, 2024Dr Nadeem discusses his case details and shares his initial thoughts. He then reviews the current treatment landscape for relapsed/refractory multiple myeloma, including his experience with bispecifics in practice and his challenges in using them. Video content above is prompted by the followingBriefly discuss your case details and share your initial thoughts. Can you briefly review the current treatment landscape for patients with relapsed/refractory multiple myeloma?

Dec 3, 2024 | cancernetwork.com | Omar Nadeem

December 3, 2024Dr Nadeem discusses his case details and shares his initial thoughts. He then reviews the current treatment landscape for relapsed/refractory multiple myeloma, including his experience with bispecifics in practice and his challenges in using them.

Jul 28, 2024 | cgtlive.com | Omar Nadeem |Victoria Johnson

BMS-986393, a GPRC5D-targeted chimeric antigen receptor (CAR) T-cell therapy, was well-tolerated and yielded responses in patients with relapsed/refractory multiple myeloma and 1-to-3 lines of prior therapy, according to initial data from the phase 1 CC95266MM001 study (NCT04674813).

Jun 14, 2024 | cgtlive.com | Omar Nadeem

“This [presentation is] basically highlighting the activity of this GPRC5D CAR T-cell product in earlier rounds of therapy in a high-risk patient population, the favorable toxicity profile, and a very high response rate of 96% with a complete response rate of 32%.”BMS-986393, a GPRC5D-targeted chimeric antigen receptor (CAR) T-cell therapy, was well-tolerated and yielded responses in patients with multiple myeloma and 1-to-3 lines of prior therapy.

Feb 29, 2024 | mdpi.com | Omar Nadeem |Sikander Ailawadhi |Jack Khouri |Louis Williams

All articles published by MDPI are made immediately available worldwide under an open access license. No specialpermission is required to reuse all or part of the article published by MDPI, including figures and tables. Forarticles published under an open access Creative Common CC BY license, any part of the article may be reused withoutpermission provided that the original article is clearly cited. For more information, please refer tohttps://www.mdpi.com/openaccess.